V113I (p.Val113Ile) variant of ABL2 (Tyrosine-protein kinase ABL2)
V113I (p.Val113Ile) in ABL2 (Tyrosine-protein kinase ABL2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.38 / 1. The record also includes population frequency data.
V113I (p.Val113Ile) variant details
- p.Val113Ile
- rs201168871
- NCI-TCGA Cosmic COSV1007
- cosmic curated COSV10077
- NCI-TCGA Cosmic COSV6101
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.38
- REVEL 0.11
- CADD 23.00
- PolyPhen-2 0.48
- SIFT 0.09
- UniProt: Variant assessed as somatic; moderate impact.
- Population evidence available